Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Fortinet Inc (FTNT) Price & Performance

Cassava Sciences IncTrade
Fortinet IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Fortinet Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Fortinet Inc trades at $161.24 (market cap $120.53B). The key difference: Fortinet Inc is far larger — about 2268.2× Cassava Sciences Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAFTNT
Market Cap
$53.14M$120.53B
Sector
HealthTechnology
52-Week High
$4.64$166.83
52-Week Low
$1.09$74.39
Enterprise Value
-$33.43M$117.73B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Fortinet Inc

Fortinet (FTNT) trades at $161.46, down 3.22% today, but maintains a bullish technical signal with strong moving averages and support near $162. The company reported consistent earnings beats, with Q1 2026 EPS of $0.82 surpassing the $0.619 estimate, and demonstrates robust fundamentals including 80.3% gross margins and 27.49% net income margin. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with Fortinet expanding its FortiEndpoint platform for AI security (GlobeNewsWire, July 14, 2026).

Outlook is positive due to AI cybersecurity tailwinds and earnings momentum, but high valuation ratios (P/E of 63.76, P/S of 17.5) pose risks if growth slows. Analyst consensus is mixed with 42.65% buy ratings, though the $123.16 price target suggests caution relative to current levels. Key risks include competitive pressures and reliance on enterprise IT spending cycles.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Fortinet Inc

Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.

Read more on FTNT